Logo image of BLUE

BLUEBIRD BIO INC (BLUE) Stock Fundamental Analysis

NASDAQ:BLUE - Nasdaq - US09609G2093 - Common Stock - Currency: USD

4.14  -0.01 (-0.24%)

Fundamental Rating

1

Taking everything into account, BLUE scores 1 out of 10 in our fundamental rating. BLUE was compared to 568 industry peers in the Biotechnology industry. Both the profitability and financial health of BLUE have multiple concerns. BLUE is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

BLUE had negative earnings in the past year.
In the past year BLUE has reported a negative cash flow from operations.
In the past 5 years BLUE always reported negative net income.
In the past 5 years BLUE always reported negative operating cash flow.
BLUE Yearly Net Income VS EBIT VS OCF VS FCFBLUE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200M -400M -600M -800M

1.2 Ratios

The Return On Assets of BLUE (-52.30%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -52.3%
ROE N/A
ROIC N/A
ROA(3y)-44.86%
ROA(5y)-61.46%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BLUE Yearly ROA, ROE, ROICBLUE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400 600

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for BLUE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BLUE Yearly Profit, Operating, Gross MarginsBLUE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5K -10K -15K -20K

More info and screens

0

2. Health

2.1 Basic Checks

BLUE does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for BLUE has been increased compared to 1 year ago.
The number of shares outstanding for BLUE has been reduced compared to 5 years ago.
Compared to 1 year ago, BLUE has a worse debt to assets ratio.
BLUE Yearly Shares OutstandingBLUE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
BLUE Yearly Total Debt VS Total AssetsBLUE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.2 Solvency

BLUE has an Altman-Z score of -15.81. This is a bad value and indicates that BLUE is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of BLUE (-15.81) is worse than 81.69% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -15.81
ROIC/WACCN/A
WACC6.56%
BLUE Yearly LT Debt VS Equity VS FCFBLUE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M 1B 1.5B

2.3 Liquidity

A Current Ratio of 0.48 indicates that BLUE may have some problems paying its short term obligations.
BLUE has a Current ratio of 0.48. This is amonst the worse of the industry: BLUE underperforms 93.13% of its industry peers.
A Quick Ratio of 0.28 indicates that BLUE may have some problems paying its short term obligations.
With a Quick ratio value of 0.28, BLUE is not doing good in the industry: 94.72% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.48
Quick Ratio 0.28
BLUE Yearly Current Assets VS Current LiabilitesBLUE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B

More info and screens

6

3. Growth

3.1 Past

BLUE shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -1231.59%.
The Revenue has grown by 183.76% in the past year. This is a very strong growth!
The Revenue has been growing by 183.97% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-1231.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-295.63%
Revenue 1Y (TTM)183.76%
Revenue growth 3Y183.97%
Revenue growth 5YN/A
Sales Q2Q%391.72%

3.2 Future

The Earnings Per Share is expected to grow by 16.11% on average over the next years. This is quite good.
The Revenue is expected to grow by 52.26% on average over the next years. This is a very strong growth
EPS Next Y59.41%
EPS Next 2Y27.64%
EPS Next 3Y21.77%
EPS Next 5Y16.11%
Revenue Next Year259.42%
Revenue Next 2Y89.08%
Revenue Next 3Y68.88%
Revenue Next 5Y52.26%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
BLUE Yearly Revenue VS EstimatesBLUE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M
BLUE Yearly EPS VS EstimatesBLUE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -50 -100 -150 -200 -250

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

BLUE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BLUE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BLUE Price Earnings VS Forward Price EarningsBLUE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BLUE Per share dataBLUE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -10 -20

4.3 Compensation for Growth

BLUE's earnings are expected to grow with 21.77% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.64%
EPS Next 3Y21.77%

More info and screens

0

5. Dividend

5.1 Amount

BLUE does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BLUEBIRD BIO INC

NASDAQ:BLUE (4/17/2025, 8:04:21 PM)

4.14

-0.01 (-0.24%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-27 2025-03-27/amc
Earnings (Next)05-07 2025-05-07/bmo
Inst Owners31.31%
Inst Owner Change0%
Ins Owners0.45%
Ins Owner Change10.43%
Market Cap40.53M
Analysts73.33
Price Target7.34 (77.29%)
Short Float %20.67%
Short Ratio5.69
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)34.09%
Min EPS beat(2)16.57%
Max EPS beat(2)51.6%
EPS beat(4)4
Avg EPS beat(4)22.32%
Min EPS beat(4)1.18%
Max EPS beat(4)51.6%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-1.44%
Min Revenue beat(2)-42.36%
Max Revenue beat(2)39.48%
Revenue beat(4)1
Avg Revenue beat(4)-11.16%
Min Revenue beat(4)-42.36%
Max Revenue beat(4)39.48%
Revenue beat(8)1
Avg Revenue beat(8)-25.56%
Revenue beat(12)3
Avg Revenue beat(12)-10.33%
Revenue beat(16)3
Avg Revenue beat(16)-30.13%
PT rev (1m)-65.05%
PT rev (3m)-80.91%
EPS NQ rev (1m)-4.78%
EPS NQ rev (3m)-1900.47%
EPS NY rev (1m)-12%
EPS NY rev (3m)-13.85%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)9.54%
Revenue NY rev (1m)3.25%
Revenue NY rev (3m)8.31%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.48
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-24.75
EYN/A
EPS(NY)-10.05
Fwd EYN/A
FCF(TTM)-26.83
FCFYN/A
OCF(TTM)-26.56
OCFYN/A
SpS8.56
BVpS-3.22
TBVpS-4.77
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -52.3%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-44.86%
ROA(5y)-61.46%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.18
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 4.24%
Cap/Sales 3.1%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.48
Quick Ratio 0.28
Altman-Z -15.81
F-Score3
WACC6.56%
ROIC/WACCN/A
Cap/Depr(3y)100.07%
Cap/Depr(5y)113.4%
Cap/Sales(3y)133.58%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1231.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-295.63%
EPS Next Y59.41%
EPS Next 2Y27.64%
EPS Next 3Y21.77%
EPS Next 5Y16.11%
Revenue 1Y (TTM)183.76%
Revenue growth 3Y183.97%
Revenue growth 5YN/A
Sales Q2Q%391.72%
Revenue Next Year259.42%
Revenue Next 2Y89.08%
Revenue Next 3Y68.88%
Revenue Next 5Y52.26%
EBIT growth 1Y20.6%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year59.48%
EBIT Next 3Y25.28%
EBIT Next 5Y23.51%
FCF growth 1Y-7.59%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-10.63%
OCF growth 3YN/A
OCF growth 5YN/A